Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1984828 | 0.83 | CYP2D6 (0.36) | KDM4EPOLBKMT2ATDP1ITGB3 | |
| Fosfocreatine SCHEMBL9074840 | 0.80 | — | — | |
| SCHEMBL9889352 | 0.75 | INMT (0.37) | — | |
| SCHEMBL8374845 | 0.69 | KDM4E (0.36) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL14510749 | 0.68 | KDM4E (0.37) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL938191 | 0.67 | KMT2A (0.39) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL11227178 | 0.66 | KDM4E (0.44) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL6070489 | 0.62 | KMT2A (0.44) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL17234253 | 0.61 | CYP2D6 (0.44) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL7504798 | 0.61 | KMT2A (0.51) | KDM4EMEN1POLBMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0426100-B1 | Stabilized enzyme compositions | ABBOTT LAB (US) | 1994-12-14 | — | — | EP | claimed |
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-20230285338-A9 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | WASHINGTON UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230248751-A1 | NOVEL BIOENERGETIC/ANTI INFLAMMATORY THERAPY | NOUR HEART, INC. | 2023-08-10 | — | — | US | disclosed |
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210393563-A1 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-23 | — | — | US | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20100303840-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENA GROUP, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100226870-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100179106-A1 | MITOCHONDRIAL COMPOSITIONS AND USES THEREOF | GENCIA CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20090298943-A1 | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disorders | AVICENA GROUP, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20080119450-A1 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | AVICENA GROUP, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20070253944-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-7285573-B2 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | AVICENA GROUP, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7186754-B2 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-6706764-B2 | TREATMENT OF DIABETIC AND TOXIC NEUROPATHIES, PERIPHERAL NERVOUS SYSTEM DISEASES, ALZHEIMER DISEASE, PARKINSON'S DISEASE, STROKE, HUNTINGTON'S DISEASE, AMYOTROPIC LATERAL SCLEROSIS | AVICENA GROUP, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-0426100-B1 | Stabilized enzyme compositions | ABBOTT LAB (US) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | KDM4E 3385/4885MEN1 3453/4885POLB 262/4885 |
| US-20100303840-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | CKMT1A; CKMT1B, PC, PCK2 | KDM4E 3280/4885MEN1 4080/4885POLB 611/4885 |
| US-20100226870-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | KDM4E 1339/4885MEN1 3935/4885POLB 352/4885 |
| US-20070253944-A1 | Use of creatine or creatine compounds for skin preservation | PC, CKMT1A; CKMT1B, CHEK1 | KDM4E 1339/4885MEN1 3935/4885POLB 352/4885 |
| US-20090298943-A1 | Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disorders | CKMT1A; CKMT1B, PCK1, TKT | KDM4E 1038/4885MEN1 4302/4885POLB 2134/4885 |
| US-20210393563-A1 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | CHRNB2, PSEN2, CX3CR1 | KDM4E 3658/4885MEN1 4782/4885POLB 3048/4885 |
| US-20230285338-A9 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | CX3CR1, CD68, FYN | KDM4E 2583/4885MEN1 4815/4885POLB 3178/4885 |
| US-20100179106-A1 | MITOCHONDRIAL COMPOSITIONS AND USES THEREOF | PC, CKMT1A; CKMT1B, SLC25A1 | KDM4E 3841/4885MEN1 594/4885POLB 973/4885 |
| US-20080119450-A1 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | CKMT1A; CKMT1B, PC, PCK2 | KDM4E 3280/4885MEN1 4080/4885POLB 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.